BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Form 8-K — Aug 14, 2026
BrainStorm Cell Therapeutics reported a second-quarter 2026 net loss of approximately $3.9 million, widening from $2.9 million in Q2 2025, with cash, cash equivalents and restricted cash of just $0.2 million at June 30, 2026, down from $1.03 million a year earlier. The balance sheet shows total liabilities of $12.4 million against total assets of $0.8 million and a stockholders' deficit of $11.6 million, while first-half 2026 capital raises totaled only about $2.4 million versus a $6.0 million H1 net loss, leaving a severe funding gap.
Key figures
- Total Debt
- 1261000
- Total Assets
- 788000
- Shares Outstanding
- 11034775
- Restricted cash
- 187000
- Accounts payable
- 7488000
- Total liabilities
- 12385000
- Ga expense q2 2025
- 1453000
- Ga expense q2 2026
- 2650000
- Rd expense q2 2025
- 1120000
- Rd expense q2 2026
- 963000
- Cash and equivalents
- 22000
- H1 2026 capital raised
- 2400000
- May 2026 private placement
- 400000
- Employees related liability
- 3069000
- Endurance planned enrollment
- 200
- February 2026 private placement
- 2000000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.